

# WORLDWIDE REGISTRATION

Cabotegravir Long-acting (LA) for PrEP

## APPROVAL

US

Australia

Zimbabwe

South Africa

## SUBMISSION

Malawi

Botswana

Brazil

Kenya

Uganda

Vietnam

Malaysia

Myanmar

Philippines

China

European Medicines Agency (EMA)

Thailand

- ✓ "Approval" means: Marketing Authorisation has been granted by a country or there is no formal regulatory process in place, in the relevant country.
- ✓ Granted Marketing Authorisations may include limitations on the use of the product.

*This document was prepared on 29 Nov 2022 and will be updated on a quarterly basis by ViiV Healthcare. It is made available for information purposes only and ViiV Healthcare accepts no liability arising from the reliance by third parties, on the information provided.*